Cross-protection among group B arboviruses has been described, on numerous occasions, in several laboratory hosts (3, 9, 13, 14, (17) (18) (19) (20) (21) . Studies on the relationships between the closely related complex of viruses that include Japanese B encephalitis (JBE), St. Louis encephalitis (SLE), Murray Valley encephalitis, and West Nile viruses have primarily used the hamster, because of its susceptibility to West Nile and Murray Valley encephalitis viruses by peripheral inoculation (9, 13, 18, 20) . The potential ability of dengue viruses to produce cross-protection against JBE and SLE viruses was not examined in that model, but was examined against West Nile virus (18, 20) . Attempts to demonstrate cross-protection between dengue and West Nile viruses in mice were reported as successful by Bond (Ph.D., University of Pittsburgh, Pittsburgh, Pa., 1967) and as unsuccessful by Price and Thind (18) . Due to loss of susceptibility of young adult mice to peripherally inoculated SLE, the challenge tests by Bond had to be made before the 4th week of age; therefore, they might have little significance. With epidemiological evidence of possible cross-protection influences of dengue infection on JBE and SLE disease in man (2, 8, 11) , this study was undertaken to develop a mouse model in which to test satisfactorily the ability of various types and strains of dengue viruses to induce an altered host immune status which would confer protection against peripheral challenge of JBE or SLE virus. It was planned to extend the time period of the former, relatively short-term hamster and mouse studies to determine whether the protection was short-lived or of long duration. MATERIALS Table 2 .
At 2-day intervals after challenge, three mice from each group were bled, and their brains were removed. Sera and brains were stored individually at -70 C until tested.
Titers of viremia and virus in the brain were assayed in suckling mice. Individual sera were diluted 1:5 and 1: 15 (vol/vol) in normal rabbit serum-sucrose phosphate glutamate (10), and then 0.01 ml of each dilution was inoculated ic. Individual brains were triturated to 10% (wt/ vol) suspensions in buffered saline (pH 7.4). Tenfold dilutions of this material were made in the above diluent, and 0.01 ml of each dilution was inoculated ic in each of eight mice. Neutralizing antibody assays were performed by the plaque reduction method.
The course of JBE virus infection differed markedly between the three treatment groups (Tables 5-7) . Immunized mice treated with CY showed rather sporadic, low-titered viremias ( (days after challenge) CY, showed only minimal signs of infection. There was low-titered viremia, which was detected in two mice 2 days after challenge (Table  5) . No virus was detected in the brains (Table  6 ), but a neutralizing antibody response was detectable 8 days after challenge (Table 7) . DISCUSSION Albino Swiss mice, immunized with any of several strains or types of dengue virus, were protected against peripheral JBE or SLE virus challenge. Protection was resistant to CY treatment administered with challenges and, as measured in dengue-2 (New Guinea "C")-immunized mice, remained undiminished for at least 20 weeks after immunization.
The results suggest that the immunizing and challenge viruses share antigens that are involved in the induction of an altered immune status responsible for protection. Protection might then be effected by pre-existing crossreactive antibody, an anamnestic antibody response elicited by the hypothesized common antigen, or by some facet of a cell-mediated response. Our experiments did not rigorously differentiate between these possibilities; thus, we can only speculate as to their relative importance.
Prechallenge neutralizing antibody levels to challenge viruses were not correlated with levels of protection. Therefore, it seems unlikely that this was the sole factor involved. However, this facet of the system needs more study, especially since the serological data were derived from serum pools. With this, the degree of individual variability and, thus, the effect of such variability on the outcome of each challenge is not known. Towards this end, passive immunization studies might give more definitive results.
The data from experiments utilizing CY treatment did not support the hypothesis (3, 17) that an anamnestic neutralizing antibody response to the challenge virus, as measured by serum antibody levels, was responsible for protection. Tables 5 and 6 indicate that the critical points of JBE virus pathogenesis (viremia, virus replication in the brain (1)) occur in CYtreated, unimmunized mice about 6 days after infection. These were resolved or prevented in CY-treated, immunized mice well before serum neutralizing antibody was detected (Table 7) . If these animals had been developing an anamnestic neutralizing antibody response, it would have been readily detectable in this experiment (Table 7) . Lending some support to this, data from survivor serum pools of CY challenge experiments (Tables 2, 3, 4) indicated that protection was not correlated with increases in levels of neutralizing antibody to the challenge virus. The data support the hypotheses of Hammon (8), Hammon et al. (11) , and Bond and Hammon (2), originally based on epidemiological evidence that, in man, prior exposure to dengue confers some degree of protection against JBE and SLE disease. However, the strength of this support rests on the degree to which analogous immune mechanisms might participate. The pathogenesis of JBE and SLE viruses appears to be, at least superficially, similar in both hosts, i.e., hematogenous spread of the virus from extraneural foci to the central nervous system (1, 12, 16) . Therefore, it is possible that similar mechanisms might be involved in preventing JBE or SLE disease.
A more difficult problem lies in defining the circumstances under which cross-protection in humans might occur. Serological data from recent studies (5-7) of a JBE epidemic in northern Thailand (a focus of endemic dengue) present evidence tentatively not supporting these hypotheses (5? 6) . Grossman et al. (5, 6) concluded that persons with pre-existing group B antibody (presumably dengue) were not guaranteed protection against encephalitis after JBE virus infection. Thus, if the phenomenon of cross-protection between dengue and JBE does, in fact, occur in humans, it is by no means absolute (2, 8, 11) and may require factors in addition to prior infection by dengue viruses.
